CD-001: A Promising Novel Dual-Targeting Immunotherapy
/0 Comments/in Immunotherapy, Preclinical Research/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/0 Comments/in Immunotherapy, Preclinical Research/by MaxAI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/0 Comments/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxAndrogen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent June 12, 2025
- Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials June 11, 2025
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025